TY  - JOUR
AU  - Abrisqueta, Pau
AU  - Loscertales, Javier
AU  - Terol, Maria José
AU  - Ramírez Payer, Ángel
AU  - Ortiz, Macarena
AU  - Pérez, Inmaculada
AU  - Cuellar-García, Carolina
AU  - Fernández de la Mata, Margarita
AU  - Rodríguez, Alicia
AU  - Lario, Ana
AU  - Delgado, Julio
AU  - Godoy, Ana
AU  - Arguiñano Pérez, José Mª
AU  - Berruezo, Mª José
AU  - Oliveira, Ana
AU  - Hernández-Rivas, José-Ángel
AU  - García Malo, Maria Dolores
AU  - Medina, Ángeles
AU  - García Martin, Paloma
AU  - Osorio, Santiago
AU  - Baltasar, Patricia
AU  - Fernández-Zarzoso, Miguel
AU  - Marco, Fernando
AU  - Vidal Manceñido, Mª Jesús
AU  - Smucler Simonovich, Alicia
AU  - López Rubio, Montserrat
AU  - Jarque, Isidro
AU  - Suarez, Alexia
AU  - Fernández Álvarez, Rubén
AU  - Lancharro Anchel, Aima
AU  - Ríos, Eduardo
AU  - Losada Castillo, María Del Carmen
AU  - Pérez Persona, Ernesto
AU  - García Muñoz, Ricardo
AU  - Ramos, Rafael
AU  - Yáñez, Lucrecia
AU  - Bello, José Luis
AU  - Loriente, Cristina
AU  - Acha, Daniel
AU  - Villanueva, Miguel
PY  - 2021
DO  - 10.1016/j.clml.2021.07.022
UR  - https://hdl.handle.net/10668/25348
T2  - Clinical lymphoma, myeloma & leukemia
AB  - Ibrutinib demonstrated remarkable efficacy and favorable tolerability in patients with untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including those with high-risk genetic alterations. The IBRORS-CLL study assessed the...
LA  - en
KW  - Chronic lymphocytic leukemia (CLL)
KW  - Effectiveness
KW  - First-line
KW  - Ibrutinib
KW  - Real-world
KW  - Relapsed/refractory (R/R)
KW  - Adenine
KW  - Aged
KW  - Humans
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - Piperidines
KW  - Pyrazoles
KW  - Pyrimidines
KW  - Retrospective Studies
KW  - Spain
TI  - Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
TY  - research article
VL  - 21
ER  -